Literature DB >> 17458558

Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count.

Ossama Tawfik1, Bruce F Kimler, Marilyn Davis, Christopher Stasik, Sue-Min Lai, Matthew S Mayo, Fang Fan, John K Donahue, Ivan Damjanov, Patricia Thomas, Carol Connor, William R Jewell, Holly Smith, Carol J Fabian.   

Abstract

Breast carcinomas are graded according to the "Nottingham modification of the Bloom-Richardson system" (SBR). The system is hindered, however, by lack of precision in assessing all three parameters including nuclear grade, mitosis, and tubular formation, leading to an element of subjectivity. Our objective was to evaluate a new grading system [the nuclear grade plus proliferation (N+P) system] for subjectivity, ease, and better representation of tumor biology. Its components are nuclear grade and automated proliferation index. Invasive ductal carcinomas, consisting of 137 SBR grade I, 247 grade II, and 266 grade III, were re-evaluated by the N+P system. The two systems were compared with each other and correlated with patients' overall survival, tumor size, angiolymphatic invasion, lymph node status, and biomarker status including estrogen receptor, progesterone receptor, p53, epidermal growth factor receptor, BCL-2, and Her-2. Although there was an agreement between the two systems with histologic and prognostic parameters studied, there was 37% disagreement when grading individual tumors. Fifty-three percent of SBR grade II tumors were "down-graded" to N+P grade I, and 7% were "up-graded" to N+P grade III. Distinction among the different histologic grades for overall survival curves was better indicated by the N+P than the SBR system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17458558     DOI: 10.1007/s00428-007-0400-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  52 in total

1.  The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.

Authors:  P C Clahsen; C J van de Velde; C Duval; C Pallud; A M Mandard; A Delobelle-Deroide; L van den Broek; M J van de Vijver
Journal:  Eur J Surg Oncol       Date:  1999-08       Impact factor: 4.424

2.  Histologic grading of breast cancer. Let's do it.

Authors:  D L Page; I O Ellis; C W Elston
Journal:  Am J Clin Pathol       Date:  1995-02       Impact factor: 2.493

3.  Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases.

Authors:  P Rudolph; G MacGrogan; F Bonichon; S O Frahm; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre; R Parwaresch
Journal:  Breast Cancer Res Treat       Date:  1999-05       Impact factor: 4.872

4.  Invasive lobular carcinoma: to grade or not to grade.

Authors:  Anita L Bane; Susanna Tjan; Robert K Parkes; Irene Andrulis; Frances P O'Malley
Journal:  Mod Pathol       Date:  2005-05       Impact factor: 7.842

5.  Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers?

Authors:  P S Sinha; S Bendall; T Bates
Journal:  Eur J Surg Oncol       Date:  2000-12       Impact factor: 4.424

6.  The prognostic relevance of estimates of proliferative activity in early breast cancer.

Authors:  B V Offersen; F B Sørensen; A Knoop; J Overgaard
Journal:  Histopathology       Date:  2003-12       Impact factor: 5.087

7.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

8.  Histological grading of breast carcinomas: a study of interobserver agreement.

Authors:  P Robbins; S Pinder; N de Klerk; H Dawkins; J Harvey; G Sterrett; I Ellis; C Elston
Journal:  Hum Pathol       Date:  1995-08       Impact factor: 3.466

9.  Intralaboratory variations in the grading of breast carcinoma.

Authors:  G S Delides; G Garas; G Georgouli; D Jiortziotis; J Lecca; T Liva; J Elemenoglou
Journal:  Arch Pathol Lab Med       Date:  1982-03       Impact factor: 5.534

10.  Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.

Authors:  S E Pinder; P Wencyk; D M Sibbering; J A Bell; C W Elston; R Nicholson; J F Robertson; R W Blamey; I O Ellis
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more
  10 in total

1.  The non-crosslinking fixative RCL2®-CS100 is compatible with both pathology diagnosis and molecular analyses.

Authors:  Florence Boissière-Michot; Amélie Denouël; Nathalie Boulle; Carole Guillaume; Béatrice Orsetti; Evelyne Lopez-Crapez; Marie-Christine Chateau; Frédéric Bibeau
Journal:  Pathol Oncol Res       Date:  2012-08-15       Impact factor: 3.201

Review 2.  The role of the basal stem cell of the human breast in normal development and cancer.

Authors:  Jose Russo; Irma H Russo
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

3.  Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of American Pathologists.

Authors:  Marilyn M Bui; Michael W Riben; Kimberly H Allison; Elizabeth Chlipala; Carol Colasacco; Andrea G Kahn; Christina Lacchetti; Anant Madabhushi; Liron Pantanowitz; Mohamed E Salama; Rachel L Stewart; Nicole E Thomas; John E Tomaszewski; M Elizabeth Hammond
Journal:  Arch Pathol Lab Med       Date:  2019-01-15       Impact factor: 5.534

4.  Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.

Authors:  Jing Ping Yuan; Lin Wei Wang; Ai Ping Qu; Jia Mei Chen; Qing Ming Xiang; Chuang Chen; Sheng-Rong Sun; Dai-Wen Pang; Juan Liu; Yan Li
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

5.  Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer.

Authors:  Jia-Hui Ye; Xiao-Hua Wang; Jia-Jun Shi; Xi Yin; Cheng Chen; Yan Chen; Hong-Yan Wu; Shi Jiong; Qi Sun; Meng Zhang; Xian-Biao Shi; Guo-Ren Zhou; Shahzeb Hassan; Ji-Feng Feng; Xin-Yun Xu; Wei-Jie Zhang
Journal:  J Cancer       Date:  2021-03-15       Impact factor: 4.207

6.  Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology images.

Authors:  Suzanne C Wetstein; Vincent M T de Jong; Nikolas Stathonikos; Mark Opdam; Gwen M H E Dackus; Josien P W Pluim; Paul J van Diest; Mitko Veta
Journal:  Sci Rep       Date:  2022-09-06       Impact factor: 4.996

7.  Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity.

Authors:  Melissa B Davis; Xinyu Liu; Shiyao Wang; Jaxk Reeves; Andrey Khramtsov; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Mol Cancer       Date:  2013-05-10       Impact factor: 27.401

8.  Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast.

Authors:  Cristian Suciu; Anca Muresan; Remus Cornea; Oana Suciu; Alis Dema; Marius Raica
Journal:  Oncol Lett       Date:  2013-11-04       Impact factor: 2.967

9.  Computer-based image studies on tumor nests mathematical features of breast cancer and their clinical prognostic value.

Authors:  Lin-Wei Wang; Ai-Ping Qu; Jing-Ping Yuan; Chuang Chen; Sheng-Rong Sun; Ming-Bai Hu; Juan Liu; Yan Li
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

10.  Quantum dots-based double imaging combined with organic dye imaging to establish an automatic computerized method for cancer Ki67 measurement.

Authors:  Lin-Wei Wang; Ai-Ping Qu; Wen-Lou Liu; Jia-Mei Chen; Jing-Ping Yuan; Han Wu; Yan Li; Juan Liu
Journal:  Sci Rep       Date:  2016-02-03       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.